A note: This is the guy for whom "lyme" disease is named. James Osbourne Holmes [email protected] FTNWO
-----Original Message----- From: Katie Jay [SMTP:[email protected]] Sent: Thursday, August 03, 2000 5:16 PM To: [email protected] Subject: CS>For Lymies << File: ATT00003.html >> I'm passing along this article for those of us who have Lyme Disease. With love, Katie Subject: From "Penicillin to "Mild Silver Protein"By Dr. Willy Burgdorfer, Ph.D. >From "Penicillin to "Mild Silver Protein" An Answer to Lyme Disease "Without Antibiotics" By Dr. Willy Burgdorfer, Ph.D. Rocky Mountain Laboratories, Division of N.I.H. In 1949, Dr. Sven Hellerstrom from the Dermatalogical Clinic of Karolinska Institute in Stockholm, Sweden presented a paper "Erythema chronicum migrans Afzelius with meningitis" at the 43rd Annual Meeting of the Southern Medical Association in Cincinnati, Ohio. In presenting his case, he provided convincing evidence that both erythema and subsequent meningocerebrospinal symptoms may develop following a tick bite. He also reported on the successful treatment of his patient with penicillin, a drug shown previously by his colleague Dr. Hollstrom to be effective in the treatment of Erythema chronicum migrans (ECM). In the United States, ECM was first reported in 1970 on a physician bitten by a tick while grouse hunting in northeastern Wisconsin. The attending physician, Dr. Rudolf Scrimenti, recognized the similarity of the patient's skin reaction to the lesions of European ECM and promptly and successfully treated the patient with penicillin. The treatment of three additional patients with penicillin and of one with erythromycin resulted in complete resolution of symptoms within 48 to 72 hours. Considered unrelated to ECM were skin lesions in 13 of 51 residents in the eastern Connecticut towns of Lyme, Old Lyme, and East Haddam where, since 1972, clusters of inhabitants had been suffering of an illness characterized by recurrent attacks of asymmetric swelling and pain in large joints, especially the knee. Since such arthritic conditions were not known to be associated with ECM in Europe, the illness was thought to be a new clinical entity and was named Lyme arthritis, later changed to Lyme disease once it was realized thatarthritis was only one of several clinical manifestations of this disease. The search for effective antibiotics in the treatment of Lyme disease began in 1982 with my discovery of a spirochete now known as Borrelia burgdorferi as the causative agent of Lyme disease and of ECM and related disorders (acrodermatitis chronica atrophicans, lymphadenosis benigna cutis) in Europe. The antibiotics found effective include tetracyclines (doxycycline, minocycline), penicillins (penicillin G, amoxycillin), cephalosporins (cefataxim, ceftriaxone), and erythromycin. Application of these drugs depends on the time the disease is being diagnosed. Early Lyme disease is treated orally whereas late Lyme disease requires parenteral or a combination of parenteral and oral applications. Treatment failures have been reported for each of these drugs particularly for the tetracyclines that are only temporarily effective unless they are applied over long periods of time, i.e. months even years. Booklet Page #13 Controversy exists over the length of treatment using Mild Silver Protein (MSP). Some investigators consider 21 to 30 days sufficient for the elimination of the spirochetes, while others believe that patients must be on therapy until they are completely free of symptoms.* The diagnosis of Lyme disease is a clinical one and is based on the development and recognition of the skin lesion (erythema migrans) a few days, weeks, or even months, after the bite of an infected tick. Unfortunately in up to 40% of the patients, the skin lesion does not develop, is not recognized, or is overlooked. Thus, without treatment, the disease spreads throughout the body and may affect the muscular, skeleton, cardiac and nervous systems. Indeed, Dr. Farber's recent claim having used MSP to successfully cure himself from late stage Lyme disease, comes at a time when thousands of patients suffering of this disease are refused extended antibiotic treatment because their physicians are unable to associate their clinical manifestations with those of Lyme disease. Although never established scientifically, it appears that the Mild Silver Protein silver colloid disables the enzyme(s) used by bacterial, fungal and viral agents for their oxygen metabolism causing them to suffocate upon contact. In vitro studies with Mild Silver Protein and the Lyme disease spirochete, B. burgdorferi, revealed a 100% killing effect within less than five minutes after exposure to the silver preparation.* Return to Table of Contents ---------------------------------------------------------------------------- ---- Booklet Page #14 TRIAL RESULTS OF MILD SILVER PROTEIN IN LYME DISEASE* Preliminary laboratory studies on Borrelia burgdorferi spirochetes revealed that mild silver protein solutions reduce the growth rate of these cells significantly and eventually lead to cell death. It has been pointed out, however, that the spirochetes tested belong to a laboratory ATCC strain which is widely used in cell and tissue cultures and does not represent recent isolates from Lyme disease patients. In these tests, various concentrations of silver protein solutions were added to the culture of Borrellia spirochetes. Low concentrations of a silver protein solution (ranging from 2 to 10 parts per million) slowed the growth rate of the spirochetes over a time span of 1 to 3 days. Higher concentrations of silver protein (between 15 to 75 parts per million) had a much faster deleterious effect on cell replication. Growth inhibition depended on the concentration of the silver protein and on the duration of treatment. More studies are definitely necessary to obtain a clearer picture of the interaction between the silver protein and Borrelia burgdorferi. As these very preliminary studies suggest, growth and replication of Lyme spirochetes are measurably inhibited by silver protein in the in vitro setting. Manfred E. Bayer, M.D. Senior Member Fox Chase Cancer Center, Institute for Cancer Research Philadelphia, PA 19111 Margret H. Bayer, Ph.D. Senior Research Associate Fox Chase Cancer Center, Institute for Cancer Research Philadelphia, PA 19111 -- The silver-list is a moderated forum for discussion of colloidal silver. To join or quit silver-list or silver-digest send an e-mail message to: [email protected] -or- [email protected] with the word subscribe or unsubscribe in the SUBJECT line. To post, address your message to: [email protected] Silver-list archive: http://escribe.com/health/thesilverlist/index.html List maintainer: Mike Devour <[email protected]>
